Peripheral Neuropathic Pain Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research & Programmes

"DelveInsight's Peripheral Neuropathic Pain Pipeline Insights 2023 report provides comprehensive insights about 10+ companies and 10+ drugs in the Peripheral Neuropathic Pain Pipeline Landscape"

DelveInsight's, "Peripheral Neuropathic Pain Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Peripheral Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Peripheral Neuropathic Pain Pipeline Report
• Peripheral Neuropathic Pain Pipeline report offers a comprehensive analysis of 10+ companies and 10+ drugs.
• The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Neuropathic Pain.
• Peripheral Neuropathic Pain emerging therapies included such as Haisco Pharmaceutical Group, AlzeCure, and several others.
• Peripheral Neuropathic Pain Companies included such as Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and several others.

Download a PDF Sample Copy of the Peripheral Neuropathic Pain Clinical Trials Report, visit here- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Neuropathic Pain Overview
Neuropathic pain is defined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain (NP) is not a particular disease, but the clinical condition that is caused by a variety of different diseases and lesions, injuring the nervous system at peripheral or central level, resulting in peripheral NP or central NP, respectively. The nerve damage and subsequent functional and structural neuroplasticity in sensory and autonomic nervous system, may become pathological and maladaptive in certain percentage of patients, and the risk of maladaptation depends on biological, genetic, demographic, and psychosocial factors. The nerve damage induces extensive response in immune system as well, resulting in close interactions between nervous and immune system, and finally neuroinflammation. Neuropathic pain (NP) can result from injury to either the central or peripheral nervous system.

Peripheral Neuropathic Pain Pipeline Report
Peripheral Neuropathic Pain Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Peripheral Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Peripheral Neuropathic Pain Emerging Drugs

HSK 16149: Haisco Pharmaceutical Group
HSK16149 is a potent ligand of VGCC α 2 δ subunit with a better therapeutic index. Hence, it could be an effective and safe drug candidate for treating chronic pain. In a study, HSK16149 was found to be a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit. HSK16149 inhibited gabapentin binding to the α 2 δ subunit and was 23 times more potent than pregabalin. In two rat models of neuropathic pain, the minimum effective dose (MED) of HSK16149 was 10 mg/kg, and the efficacy was similar to that of 30 mg/kg pregabalin. Moreover, the efficacy of HSK16149 could persist up to 24 hours post administration at 30 mg/kg, whereas the efficacy of pregabalin lasted only for 12 hours at 30 mg/kg in streptozotocin-induced diabetic neuropathy model, indicating that HSK16149 might be a longer-acting drug candidate. HSK16149 could also inhibit mechanical allodynia in intermittent cold stress model and decrease phase II pain behaviors in formalin-induced nociception model.

ACD 440: AlzeCure
ACD440 is a TRPV1 antagonist that originated in Big Pharma and is based on a strong scientific foundation. The discovery and insight into TRPV1, the biological system that underlies ACD440 and is central to, among other things, temperature regulation and pain, was awarded the Nobel Prize in Physiology or Medicine 2021. The compound has previously undergone Phase I clinical trials, in which both good tolerability and early positive signals of efficacy were observed. The mechanism of action of the project is via TRPV1 receptors, which have a key role in pain signaling, and ACD440 has been shown in preclinical trials to have an effect on both nociceptive and neuropathic pain. The compound has previously undergone extensive preclinical safety studies and since the compound is being developed for local use, systemic exposure can be kept very low, while the concentration of the compound locally can be kept high for maximum analgesic effect.

Get to know more information of the Peripheral Neuropathic Pain Emerging Therapies and Companies- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Neuropathic Pain Pipeline Phases
DelveInsight's report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Peripheral Neuropathic Pain Pipeline Analysis
The report provides insights into:-
• The report provides detailed insights about companies that are developing therapies in the Peripheral Neuropathic Pain Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Neuropathic Pain treatment.
• Peripheral Neuropathic Pain key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peripheral Neuropathic Pain Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Peripheral Neuropathic Pain market.

To know more facts about the Peripheral Neuropathic Pain Pipeline Report, View Here- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Neuropathic Pain Pipeline Therapeutic Analysis
There are approx. 10+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II/III include, Haisco Pharmaceutical Group.

Scope of the Peripheral Neuropathic Pain Pipeline Report
• Coverage- Global
• Peripheral Neuropathic Pain emerging therapies included such as Haisco Pharmaceutical Group, AlzeCure, and several others.
• Peripheral Neuropathic Pain Companies included such as Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and several others.

Find out the information of the peripheral neuropathic pain emerging drugs, companies of the report @ https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Peripheral Neuropathic Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral Neuropathic Pain- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Last Stage Products (Phase II/ III)
10. HSK 16149: Haisco Pharmaceutical Group
11. Mid Stage Products (Phase II)
12. ACD 440: AlzeCure
13. Preclinical and Discovery Stage Products
14. Drug Name : Company Name
15. Inactive Products
16. Peripheral Neuropathic Pain Key Companies
17. Peripheral Neuropathic Pain Key Products
18. Peripheral Neuropathic Pain - Unmet Needs
19. Peripheral Neuropathic Pain - Market Drivers and Barriers
20. Peripheral Neuropathic Pain - Future Perspectives and Conclusion
21. Peripheral Neuropathic Pain Analyst Views
22. Peripheral Neuropathic Pain Key Companies
23. Appendix

For any query related to the Peripheral Neuropathic Pain Pipeline Report, then speak to the analyst here- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.